Research - NYCVA - Heart attack information - Our research helps!
Call (646) 233-1838
160 West 26th Street
Third Floor
New York, NY 10001

Yelp g+ facebook twitter youtube blog


Patient Focused


Gotham Cardiovascular Research was founded by New York Cardiovascular Associates to help contribute to the development of new and potentially groundbreaking advances in medical care. It is committed to participating in clinical trials which study the development of new therapies and diagnostic tools with the goal of better managing and eventually finding cures for cardiovascular and pulmonary disease. We feel it is crucial to be a part of clinical research to allow our doctors, staff and patients have access to the most advanced therapies. This can only be achieved by participation in clinical trials.

Dr. Cezar Staniloae, Director of Gotham Cardiovascular Research, and the entire research team have been involved with over a hundred clinical research studies. Currently, the team is involved with sixteen cardiovascular studies focusing on various therapeutic regimens.



Clinical research is the manner which the medical community is able to study a disease process in a non-biased blinded manner. Patients will be given medications and/or have a medical procedure which can then be evaluated for safety and potential efficacy.

A patient who enrolls in a clinical trial is donating a tremendous service to help treat a disease process.



1) HPS 3 / TIMI 55: REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease.

2) IMPROVE IT: (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): This study compares Vytorin® (ezetimibe/simvastatin) to Simvastatin in patients who have been stabilized after being hospitalized for an acute coronary syndrome to learn if Vytorin® is superior in reducing recurrent cardiac events.

3) LDL4758g: A multicenter, randomized, double-blind, placebo-controlled phase II study to evaluate the safety, tolerability, and activity of intravenous MLDL1278A in patients on standard-of-care therapy for stable atherosclerotic cardiovascular disease.

4) TRILOGY: A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed.

5) SOLID: The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial. A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

6) RED HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia.

7) SPIRIT PRIME Clinical Trial: A clinical Evaluation of the XIENCE PRIME and XIENCE PRIME LL Everolimus Eluting Coronary Stent System.

8) SPIRIT Small Vessel Registry: Clinical Evaluation of the 2.25 mm XIENCE V™ Everolimus Eluting Coronary Stent System.

9) RIVAROXAFL4001: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation – (ORBIT-AF).

10) SMART RISK: Performance of “SmartRisk” Prediction of Stroke and Stroke-related Events in Carotid Atherosclerosis.

11) REDUCE-IT (Reduction of Cardiovascular Events with EPA –
Intervention Trial): A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for cardiovascular Disease.
Clinical research: Need heart attack information and all other relevant studies? NYCVA’s research team is world renowned and saves lives. New York, NY.

New York Cardiovascular Associates